The aim of this study was to investigate the association of TM6SF2 rs58542926 with the risk of NAFLD and CRA, and the effect of CRA on TM6SF2 rs58542926 carried NAFLD patients. Here, TM6SF2 is linked to metabolic dysfunction-associated steatotic liver disease.